Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 34 bp deletion in exon 1.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CTDSP1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CTDSP1 also known as CTD small phosphatase 1 functions as an enzyme that dephosphorylates the C-terminal domain (CTD) of RNA polymerase II. This process regulates transcription elongation and termination. CTDSP1 has a molecular mass of approximately 30 kDa. The protein expresses widely with high levels found in the brain and ovary. It primarily operates within the nucleus reflecting its role in transcription regulation.
Biological function summary
CTDSP1 is involved in gene expression regulation by influencing RNA polymerase II activity. It belongs to a phosphatase family with related proteins like CTDSP2 and CTDSPL sharing overlapping functions. As a part of the CTD phosphatase complex CTDSP1 coordinates with other molecular players to manage gene expression outputs. This regulatory mechanism helps modulate responses to external and internal cellular signals.
Pathways
CTDSP1 takes part in the larger RNA transcription and processing pathways particularly the regulation of RNA polymerase II transcription. CTDSP1 interacts with factors like pre-mRNA splicing components affecting gene expression outcomes. It is associated with pathways that involve Cyclin-dependent kinase 9 (CDK9) which also influences RNA polymerase II activity through phosphorylation events demonstrating its key physiological interactions.
CTDSP1 has associations with neurological conditions and cancer. Its involvement in modulating gene expression links it to neurodegenerative disorders like Alzheimer's disease where transcription regulation plays a significant role in disease progression. Additionally changes in CTDSP1 activity relate to tumorigenesis with alterations in CTDSP1 or interacting proteins like CTDSP2 observed in various cancers. This makes CTDSP1 an interesting target for further research into diagnostic and therapeutic applications.
